|
|
| | MOFEBUTAZONE Basic information |
| Product Name: | MOFEBUTAZONE | | Synonyms: | 2fdbp;2-phenyl-3,5-dihydroxy-4-butylpyrazolidine;4-butyl-1-phenyl-3,5-dioxopyrazolidine;4-butyl-1-phenyl-3,5-pyrazolidinedione;4-butyl-1-phenyl-5-pyrazolidinedione;arcomonoltablets;mobutazon;mobuzon | | CAS: | 2210-63-1 | | MF: | C13H16N2O2 | | MW: | 232.28 | | EINECS: | 218-641-1 | | Product Categories: | | | Mol File: | 2210-63-1.mol |  |
| | MOFEBUTAZONE Chemical Properties |
| Melting point | 102-103° | | Boiling point | 374.44°C (rough estimate) | | density | 1.1099 (rough estimate) | | refractive index | 1.6450 (estimate) | | storage temp. | Room Temperature | | solubility | DMSO (Slightly), Methanol (Sparingly) | | form | Solid | | pka | 5.22±0.10(Predicted) | | color | White to Off-White |
| Toxicity | LD50 i.v. in mice: 600 mg/kg (Schoetensack) |
| | MOFEBUTAZONE Usage And Synthesis |
| Originator | Butaphen,Wiedenmann | | Uses | Mofebutazone is an anti-inflammatory drug used on the gastrointestinal and renal tissues. | | Definition | ChEBI: A pyrazolidine that is phenylbutazone lacking one of the phenyl substituents. It is used for treatment of joint and muscular pain. | | Manufacturing Process | A mixture comprising 108 g of phenyl hydrazine and 216 g of the diethyl ester
of n-butylmalonic acid is heated on an oil bath at 170°-180°C for 12 hours.
The residue is taken up with water in which an alkaline compound has been
dissolved and acetic acid is added to precipitate 4-n-butyl-2-phenylpyrazolidine-3,5-dione. The product is a white crystalline solid having a MP:
103°C. It is soluble in acetone and benzene, soluble in hot condition in
methanol and ethanol and insoluble in water. | | Brand name | Arcobutine;Buta lyseen;Chemiartrol;Clinit;Diadin;Fenartril;Jovapyrin;Mobutazone;Mofasal;Mofesal;Monazone;Monbutina;Monobutina;Monofen;Monomil;Monoprine;Monozon;Mozol;Rheuma-cur;Rheumaorctat;Rivodol;Sodepyrine b 1. | | Therapeutic Function | Antirheumatic, Analgesic, Antiinflammatory | | World Health Organization (WHO) | Mofebutazone, a pyrazolone with anti-inflammatory, analgesic
and antipyretic activity, was introduced in 1962 for the treatment of rheumatic
disorders. As it is structurally related to phenylbutazone it is subjected to
rigorously restricted indications by some national regulatory authorities. See WHO
comment for phenylbutazone. | | Clinical Use | Mofebutazone is a nonsteroidal
anti-inflammatory drug used as sodium
salt for the treatment of mild to moderate
pain including inflammatory and degenerative
rheumatic disorders and musculoskeletal pain.
Mofebutazone can be given by oral, rectal
(900–1200 mg/d), or intramuscular administration
(650 mg/d). |
| | MOFEBUTAZONE Preparation Products And Raw materials |
|